Vanguard Group Inc. Has $5.97 Billion Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Vanguard Group Inc. increased its stake in Regeneron Pharmaceuticals by 1.3%, holding approximately 9.4 million shares valued at nearly $6 billion.
• Analysts have mixed ratings for Regeneron, with one sell rating, seven hold ratings, and sixteen buy ratings, reflecting a consensus rating of "Moderate Buy" and an average price target of $841.30.
• Regeneron reported $12.89 EPS for the recent quarter, significantly exceeding estimates, with a revenue rise of 3.6% year-over-year.

Vanguard Group Inc. boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1.3% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 9,407,891 shares of the biopharmaceutical company's stock after purchasing an additional 121,545 shares during the period. Vanguard Group Inc. owned about 8.61% of Regeneron Pharmaceuticals worth $5,966,767,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in the business. Pinney & Scofield Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. increased its position in shares of Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 31 shares during the period. Costello Asset Management INC acquired a new stake in Regeneron Pharmaceuticals during the first quarter worth about $27,000. Tompkins Financial Corp acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $32,000. Finally, Curat Global LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $32,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Analysts Set New Price Targets

REGN has been the topic of a number of recent analyst reports. UBS Group reiterated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective for the company. in a research report on Friday, August 1st. Citigroup reissued a "buy" rating and issued a $650.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Finally, Morgan Stanley boosted their price objective on Regeneron Pharmaceuticals from $754.00 to $761.00 and gave the stock an "overweight" rating in a research report on Friday, August 1st. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $841.30.

Regeneron Pharmaceuticals Stock Down 2.6%

REGN opened at $555.13 on Thursday. The company's 50-day moving average price is $536.31 and its two-hundred day moving average price is $601.45. The company has a quick ratio of 4.73, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,211.20. The stock has a market cap of $59.93 billion, a price-to-earnings ratio of 13.99, a PEG ratio of 2.08 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. The business had revenue of $3,675,600 billion during the quarter, compared to the consensus estimate of $3.30 billion. During the same period last year, the business posted $11.56 earnings per share. The business's revenue for the quarter was up 3.6% on a year-over-year basis. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be paid a $0.88 dividend. The ex-dividend date is Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.